X

Drug Profile

AZD 1134

Latest Information Update: 31 Mar 2004

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Class Antidepressants; Anxiolytics
Mechanism of Action Serotonin 1B receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

31 Mar 2004 Discontinued - Preclinical for Anxiety disorders in USA (unspecified route)
31 Mar 2004 Discontinued - Preclinical for Depression in USA (unspecified route)
02 Oct 2003 Data presented at the 16th Congress of the European College of Neuropsychopharmacology (ECNP-2003) have been added to the Affective and Anxiety disorders pharmacodynamics section ,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com